These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 28329747)

  • 1. Influence of Dipeptidyl Peptidase-IV Inhibitor Sitagliptin on Extracellular Signal-Regulated Kinases 1/2 Signaling in Rats with Diabetic Nephropathy.
    Ren X; Liu G; Wang Y; Zhang W; Xue F; Li R; Yu W
    Pharmacology; 2017; 100(1-2):1-13. PubMed ID: 28329747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of sitagliptin on tubulointerstitial Wnt/β-catenin signalling in diabetic nephropathy.
    Ren X; Zhu R; Liu G; Xue F; Wang Y; Xu J; Zhang W; Yu W; Li R
    Nephrology (Carlton); 2019 Nov; 24(11):1189-1197. PubMed ID: 31412145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of siglidine on glucose lipid metabolism and the expression of iNOS and GLP-1 receptors in diabetic rats.
    Zhang HY; Li Y; Zhong YH; Ruan LB; Yang TR; Yin HP
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8984-8989. PubMed ID: 30575943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-Like Peptide-1 Mediates the Protective Effect of the Dipeptidyl Peptidase IV Inhibitor on Renal Fibrosis via Reducing the Phenotypic Conversion of Renal Microvascular Cells in Monocrotaline-Treated Rats.
    Xu J; Wang J; Cheng Y; Li X; He M; Zhu J; Han H; Wei G; Kong H; Xie W; Wang H; Zuo X
    Biomed Res Int; 2018; 2018():1864107. PubMed ID: 29607314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase.
    Tang ST; Su H; Zhang Q; Tang HQ; Wang CJ; Zhou Q; Wei W; Zhu HQ; Wang Y
    Int J Mol Med; 2016 Jun; 37(6):1558-66. PubMed ID: 27122056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
    Sangle GV; Lauffer LM; Grieco A; Trivedi S; Iakoubov R; Brubaker PL
    Endocrinology; 2012 Feb; 153(2):564-73. PubMed ID: 22186413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dipeptidyl peptidase-4 inhibitor sitagliptin ameliorates renal injury in type 1 diabetic mice
    Li L; Lian X; Wang Z; Zheng J; Liu J; Chu Y; Teng Y; Zhang Z
    Pharmazie; 2019 Apr; 74(4):239-242. PubMed ID: 30940309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical, apoptotic and biochemical changes by dipeptidyl peptidase-4 inhibitor-sitagliptin in type-2 diabetic rats.
    Karabulut S; Coskun ZM; Bolkent S
    Pharmacol Rep; 2015 Oct; 67(5):846-53. PubMed ID: 26398375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
    Liu WJ; Xie SH; Liu YN; Kim W; Jin HY; Park SK; Shao YM; Park TS
    J Pharmacol Exp Ther; 2012 Feb; 340(2):248-55. PubMed ID: 22025647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
    Liu L; Liu J; Wong WT; Tian XY; Lau CW; Wang YX; Xu G; Pu Y; Zhu Z; Xu A; Lam KS; Chen ZY; Ng CF; Yao X; Huang Y
    Hypertension; 2012 Sep; 60(3):833-41. PubMed ID: 22868389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: role of GLP-1 and GLP-1 receptor.
    Abd El Motteleb DM; Elshazly SM
    Eur J Pharmacol; 2013 Nov; 720(1-3):158-65. PubMed ID: 24238127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
    Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ
    Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking.
    Ramírez E; Picatoste B; González-Bris A; Oteo M; Cruz F; Caro-Vadillo A; Egido J; Tuñón J; Morcillo MA; Lorenzo Ó
    Cardiovasc Diabetol; 2018 Jan; 17(1):12. PubMed ID: 29325553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CB-1R and GLP-1R gene expressions and oxidative stress in the liver of diabetic rats treated with sitagliptin.
    Coskun ZM; Koyuturk M; Karabulut S; Bolkent S
    Pharmacol Rep; 2017 Aug; 69(4):822-829. PubMed ID: 28599244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sitagliptin and shock wave-supported peripheral blood derived endothelial progenitor cell therapy effectively preserves residual renal function in chronic kidney disease in rat-role of dipeptidyl peptidase 4 inhibition.
    Sung PH; Chen KH; Li YC; Chiang JY; Lee MS; Yip HK
    Biomed Pharmacother; 2019 Mar; 111():1088-1102. PubMed ID: 30841422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of DPP4 enhances inhibitory synaptic transmission through activating the GLP-1/GLP-1R signaling pathway in a rat model of febrile seizures.
    Zhang Y; Liu Y; Xu J; Sun Q; Yu F; Cheng J; Peng B; Liu W; Xiao Z; Yin J; Han S; He X
    Biochem Pharmacol; 2018 Oct; 156():78-85. PubMed ID: 30086287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol ameliorates early diabetic nephropathy associated with suppression of augmented TGF-β/smad and ERK1/2 signaling in streptozotocin-induced diabetic rats.
    Chen KH; Hung CC; Hsu HH; Jing YH; Yang CW; Chen JK
    Chem Biol Interact; 2011 Mar; 190(1):45-53. PubMed ID: 21300041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R; Shikata K; Takatsuka T; Oda K; Miyamoto S; Kajitani N; Hirota D; Ono T; Usui HK; Makino H
    Biochem Biophys Res Commun; 2014 Jan; 443(3):828-33. PubMed ID: 24342619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sitagliptin and Roux-en-Y gastric bypass modulate insulin secretion via regulation of intra-islet PYY.
    Guida C; McCulloch LJ; Godazgar M; Stephen SD; Baker C; Basco D; Dong J; Chen D; Clark A; Ramracheya RD
    Diabetes Obes Metab; 2018 Mar; 20(3):571-581. PubMed ID: 28892258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitagliptin attenuates intestinal ischemia/reperfusion injury via cAMP/PKA, PI3K/Akt pathway in a glucagon-like peptide 1 receptor-dependent manner.
    Khedr RM; Ahmed AAE; Kamel R; Raafat EM
    Life Sci; 2018 Oct; 211():31-39. PubMed ID: 30195035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.